



## Alzheimer's Disease—115 Years after Its Discovery

Guest Editors:

**Dr. Susana Cardoso**

Center for Neuroscience and Cell  
Biology, University of Coimbra,  
3004-504 Coimbra, Portugal

**Dr. Cristina Carvalho**

Center for Neuroscience and Cell  
Biology, University of Coimbra,  
3004-517, Coimbra, Portugal

**Dr. Sónia Catarina Correia**

Center for Neuroscience and Cell  
Biology, University of Coimbra,  
3004-517 Coimbra, Portugal

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

It has been a long journey since Alois Alzheimer, a dedicated German physician, first linked Auguste Deter's symptoms of deteriorating memory, disorientation, decreasing speech abilities, and lack of judgment to the detection of two characteristic brain lesions, neurofibrillary tangles, and extracellular deposits that were later named senile plaques—a discovery that would make his name a household term throughout the world! Now, at 115 years after this discovery, the massive international research effort has contributed to uncovering several pieces of key information about the causes and accelerators of the development of Alzheimer's disease (AD) and its progression. In this Commemorative Special Issue, we intend to present an overview of the state-of-the-art of this interesting story including the important recent advances and the latest research and milestones in AD research. We welcome papers focused on (i) diagnostic tools; (ii) in vivo and in vitro models of the disease; (iii) molecular mechanisms underlying the onset and progression of the disease; and (iv) therapeutic strategies aimed to counteract the advances of AD.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)